Endpoint Translation from Sensor Classification to Patient Benefit

Abstract

The boundary between useful assistance and an unsupported claim becomes visible when laboratory recognition accuracy assumed to improve health. A bounded review of the literature is used to formulate, rather than claim to complete, an evaluation. The primary literature contributes a bounded result: the publication synthesizes low-grade inflammation, tissue remodeling, tolerance, and disease-specific pulmonary contexts. Diagnostic recognition and patient benefit require different evaluations. A laboratory classifier can recognize a signal while failing to improve decisions or outcomes in practice. Evaluate the complete care pathway prospectively when a clinical claim is intended. Compare with current practice and assess harms as well as successful classification. The proposed comparison concerns Parkinson classification, encrypted interaction, pulmonary care; it would test whether the specific failure scenario is detected without erasing legitimate uncertainty. The original source's limits remain material: Mechanisms vary across COPD, bronchiectasis, asthma, and other contexts; proposed combined antibiofilm/immunomodulatory strategies are not proven universal treatments.